Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,289 across all filing types
Latest filing 2021-10-25 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2021 年第三季度报告" which translates to "2021 Third Quarter Report." It contains detailed financial data including income statements, balance sheets, cash flow statements, and notes on financial performance for the third quarter of 2021. The document includes unaudited financial statements and comprehensive financial metrics for the quarter and year-to-date periods. The presence of quarterly financial statements and detailed financial analysis indicates this is an Interim / Quarterly Report. The document length is about 15,000 characters, which is consistent with a full quarterly report rather than a brief announcement or certification. Therefore, the document is classified as an Interim / Quarterly Report (IR).
2021-10-25 Chinese
安图生物2021年第一次临时股东大会会议材料
AGM Information Classification · 95% confidence The document is titled as materials for the 2021 first extraordinary general meeting (临时股东大会) of Autobio Diagnostics Co., Ltd. It contains detailed agenda items, including election of board members (both independent and non-independent directors), election of supervisors, and amendments to the company's articles of association and business scope. The content includes candidate biographies, meeting procedures, voting methods, and legal compliance statements. There is no financial data or earnings information, nor is it a transcript or presentation. The document is clearly the meeting materials provided to shareholders for the extraordinary general meeting, which is a type of shareholder meeting. According to the filing definitions, materials shared during a general meeting (AGM or EGM) fall under AGM Information (AGM-R). Since this is an extraordinary shareholders meeting, the classification still fits under AGM Information. The document length is over 11,000 characters, indicating it is the full meeting materials, not just an announcement or notice. Therefore, the correct classification is AGM-R with high confidence.
2021-10-19 Chinese
安图生物关于职工代表监事换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of a new employee representative supervisor (监事) for the company's supervisory board. It details the election process, the term of office, and includes a brief resume of the elected individual. There is no financial data, no mention of financial results, no regulatory certifications, or report publications. The content relates to changes in the company's supervisory board members, which falls under Board/Management Information filings. The document length is short and it is not a report or announcement of a report publication, so it is not an RPA or RNS. Therefore, the appropriate classification is MANG (Board/Management Information).
2021-10-19 Chinese
安图生物第三届监事会第二十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 22nd meeting of the third Supervisory Board of Zhengzhou Antu Biological Engineering Co., Ltd. It includes details about the nomination of candidates for the fourth Supervisory Board and changes to the company's business scope and articles of association. The document focuses on board-level decisions and nominations, which are related to management and supervisory board information. There is no financial data, earnings information, or regulatory filings about financial performance. The document is not a full report but an announcement of board/management changes and nominations. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear content about board nominations and resolutions.
2021-10-12 Chinese
关于公司第三届董事会第二十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the nomination of candidates for the company's fourth board of directors. It references compliance with company law, governance guidelines, and the company's articles of association. The document is related to board/management matters, specifically the nomination and approval of board members, and is not a full report, financial statement, or announcement of voting results. It is not a regulatory filing or a report publication announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management nominations, supporting this classification.
2021-10-12 Chinese
安图生物章程
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 郑州安图生物工程股份有限公司. It contains detailed chapters on company organization, shareholder rights, board of directors, management, financial accounting, profit distribution, auditing, and other governance matters. The content is a comprehensive set of internal rules and regulations governing the company’s structure and operations, including shareholder meetings, board responsibilities, and capital management. There is no indication that this is an announcement, a financial report, or a regulatory filing. It is a governance document outlining the company’s internal rules and governance practices. Therefore, the appropriate classification is Governance Information (CGR).
2021-10-12 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.